L’ivermectine (Stromectol) est un antiparasitaire dont l’action repose sur la liaison sélective aux canaux chlore activés par le glutamate présents dans les cellules nerveuses et musculaires des parasites. Cette fixation entraîne une augmentation du flux de chlore, provoquant une hyperpolarisation et une paralysie irréversible. L’ivermectine est active contre la gale, l’onchocercose et certaines strongyloïdoses. Sa biodisponibilité orale est variable, augmentée par la prise alimentaire, et son élimination est principalement fécale via un métabolisme hépatique. Elle ne traverse pas la barrière hémato-encéphalique, ce qui limite les effets neurologiques chez l’homme. Les précautions concernent l’interaction avec les inhibiteurs du CYP3A4, ainsi que les réactions inflammatoires dues à la destruction massive des parasites. Dans les documents de référence, stromectol prix est associé à des protocoles précis adaptés aux différentes infestations, avec une attention particulière sur la sécurité d’emploi en cas d’immunodépression.
Angio-zuerich.ch
Dr. med. Silviana Spring FMH Angiologie und Innere Medizin
Klinik HirslandenAngiologieWitellikerstrasse 40CH-8032 Zürich T +41(0)44 387 29 25F +41(0)44 387 29 26info@angio-zuerich.chwww.angio-zuerich.ch
Publikationsliste
1. B. van der Loo, E. Krieger, J. Katavic, S. Spring, V. Rousson, B. Amann-Vesti and R. Koppensteiner. Carotid
intima-media thickness, carotid wall shear stress and restenosis after femoro-popliteal percutaneus transluminal angioplasty (PTA). Eur J Vasc Endovasc Surg. 2005 Nov;30(5):469-74.
2. S. Spring, B. van der Loo, E. Krieger, B.R. Amann-Vesti, V. Rousson, R. Koppensteiner. Decreased wall
shear stress in the common carotid artery of patients with peripheral arterial disease or abdominal aortic aneurysm: relation to blood rheology, vascular risk factors, andintima-media thickness. J Vasc Surg. 2006 Jan;43(1):56-63.
3. R. Koppensteiner, S. Spring, B. Amann-Vesti, T. Meier, T. Pfammatter, V. Rousson, M. Banyai, B. van
der Loo. Low molecular weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty (PTA): a randomised controlled trial. J Vasc Surg 2006;44:1247-53.
4. S. Spring, R. Simon, B. van der Loo, T. Kovacevic, Ch. Brockes, B. Amann-Vesti, R. Koppensteiner.
Aggressive lipid-lowering with Atorvastatin in Patients with Peripheral Arterial Disease (PAD): Effect on Endothelial Function, Intima-Media-Thickness and Local Progression of PAD - An open, prospective randomized Trial. Thromb Haemost 2008;98:182-189.
5. R. W. Simon, S. Spring, R. Luechinger, P. Boesiger, B.R. Amann-Vesti. Wall shear rate in supra-aortic ves-
sels: a factor for different atherosclerotic pattern? VASA 2008;37(3):227-32.
6. M. Husmann, T. Willenberg, H. Keo, S. Spring, E. Kalodiki, K. Delis. Integrity of veno-arteriolar reflex
determines level of microvascular flow enhancement by intermittent pneumatic compression. J Vasc Surg. 2008 Dec;48(6):1509-13.
7. B. van der Loo , F. Naef , S. Spring, V. Rousson, B. Amann-Vesti, R. Koppensteiner. Lack of major gender-
related differences in patients undergoing elective endovascular or surgical repair of abdominal aortic aneurysm. Int Angiol. 2009 Feb;28(1):50-5.
8. B. van der Loo, S. Spring, R. Koppensteiner. High dose atorvastatin treatment in patients with periphe-
ral disease: effects on platelet aggregation, blood rheology and plasma homocysteine. Clin Hemorheol Microcirc. 2011;47(4):241-51.
9. M. Husmann, Ch. Thalhammer, S. Spring, Th. Meier, M. Roffi, U. Schwarz, V. Rousson and B. R. Amann-
Vesti, MD. Influence of plaque volume on hemodynamic response and stress hormone release in patients undergoing carotid artery stenting. Int. Angiol. 2012 Feb;31(1):10-5.
10. S. Schnyder, S. Gabler, T.O. Meier, C. Thalhammer, F. Magnetti, S. Spring, B.R. Amann-Vesti. Successful
reduction of clinical relevant neovascularization with a modified crossectomy combined with a barrier technique after 10-year follow-up. Phlebology 2012 Dec;27(8):404-8.
University Hospitals/Ireland Cancer Center Sickle Cell Inpatient Treatment Guidelines Supportive Care Sickle Cell Guidelines • If patient is hypovolemic on admission, hydrate with Normal Saline @ 300 - 500 • If patient is euvolemic on admission or becomes euvolemic after hydration, hydrate with D5W1/2NS at 75-125 ml/hr continuously. Laboratory/Radiology All patient
MEDICATION DECLARATION FORM INFORMATION SHEET THE World Anti Doping Agency (WADA) has determined that some medication may confer an unfair competitive advantage and have issued a list of those drugs and other agents that are banned by competitors. Some agents on this banned list may be used for specific medical conditions and, in some instances; the drug is the only one, which is effective.